NovoCure Ltd — Director's Dealing 2018

May 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2018-05-08

Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-08	Ordinary Shares	F	28756	$28.055	Disposed	940795	Direct
2018-05-09	Ordinary Shares	F	28652	$28.257	Disposed	912143	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	43000	Indirect
Ordinary Shares	625954	Indirect

Footnotes

F1: 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018 (previously reported on a Form 4 filed on May 8, 2018), and released an additional one-fifth of the RSUs as of May 8, 2018 and one-fifth of the RSUs as of May 9, 2018. Mr. Doyle has sold sufficient RSUs to cover the tax liability. One-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017.

F2: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017.

F3: Mr. Doyle is the Managing Director of WFD Ventures LLC, the sole member of WFD-GP II LLC, which is the general partnerof WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest.